Saturday, March 16, 2024

MTR CELEBRATES 100 YEARS WITH WORLD'S LONGEST DOSA MEASURING 123 FEET -ENTERS GUINNESS WORLD RECORDS.

Celebrating 100 years MTR style-MTR Foods announced that they are now the new GUINNESS WORLD RECORDS Title holder for the Longest Dosa in partnership with Lorman Kitchen Equipments. MTR's signature Red Rice Batter was used to prepare this Longest Dosa at its Bommasandra Factory.The record was created by a team of 75 Chefs,comprising of both seasoned experts & budding culinary talent,under the guidance of MTR's Cuisine Centre of Excellence.


Mr.Sunay Bhasin,CEO of MTR said,"Dosa has been a part of MTR's legacy from the very beginning and it continues to be one of the most loved products of MTR even today.From a humble south Indian Dish,it is now recognised & loved worldwide.The longest Dosa world record is a celebration of our bond with our consumers and their favourite dish".

Mr.Chandra Mouli,MD.Lorman Kitchen Equipment Pvt.Ltd., added," World's longest dosa is being cooked on a specially built induction stove,the biggest ever from Lorman.We are proud to be associated with MTR on this remarkable event."


About MTR: A popular household name MTR is synonymous with delicious Indian food is an easy-to-use packaged format.With a diverse portfolio including many iconic products like sambar powder,Puliogare,Rava Idli,Gulab Jamun mix,Badam drink mix which are house hold names today.MTR unifies India tastefully-making the home maker the 'Hero'. MTR Pvt.Ltd., is a subsidiary of Norwegian conglomerate Orkla. Orkla India is a collection of leading local Indian food
 brands.It owns iconic heritage brands -MTR,Rasoi Magic & Eastern.

Tuesday, March 5, 2024

ROCHE LAUNCHES "VABYSMO"(faricimab),THE FIRST AND ONLY BISPECIFIC MONOCLONAL ANTIBODY FOR THE EYE,TO TREAT TWO LEADING CAUSES OF VISION LOSS.

Roche pharma India marked its foray into the opthalmology space by launching VABYSMO"(faricimab)for the treatment of neovascular or wet age related macular degeneration (nAMD)and diabetic macular edema(DME).Neovascular AMD and DME are leading causes of vision loss worldwide."Vabysmo"is the first and only dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions.Vabysmo is a single molecule designed to provide the benefits of two medicines in one.

"VABYSMO" has the potential to transform the existing standard of Care (SoC) as the burden associated with currently available treatment options for nAMD & DME such as frequent eye injections (typically required every one to two months)and physician visits can lead to under treatment and less than optimal vision outcomes.

Commenting on the launch,Mr.V.Simpson Emmanuel,CEO & Managing Director,Roche Pharma India,"We believe more should be done to meet the needs of people living with retinal conditions & to preserve sight.While there is strong awareness and action for cataract and other frontal eye-disorders,retinal conditions are often diagnosed late or neglected leading to vision loss.The Launch of "VABYSMO" marks our entry into the opthalmology space in India,underscoring our commitment to bring the best-in-class innovations to the country.With fewer eye injections over time,while also improving and maintaining vision & anatomy,"VABYSMO" offers a more convenient & effective treatment schedule for patients,their caregivers and healthcare systems".

Dr.Chaitra Jayadev,Head of Vitreoretina Services at Narayana Nethralaya Eye Institute,Said, "As retina specialists, we see this as a game changer in our field,offering new hope and possibilities for our patients battling these complex retinal diseases'.

"VABYSMO" (faricimab) was first approved by the USFDA in January,2022.It is today available in across 90+countries and more than 2 million doses have been administered till date".

It was said during the discussions, that Diabetes is one of the triggering factors for Retinal Disorders.

Saturday, March 2, 2024

HELIOS MUTUAL FUND LAUNCHES " HELIOS BALANCED ADVANTAGE FUND" (BAF).

Helios Mutual Fund announced the launch of Helios Balanced Advantage Fund (BAF),an open ended dynamic asset allocation fund.This NFO will open for subscription on March,11,2024 & Close on March 20,2024.This fund aims to capitalize on the potential upside of eauities while attempting to limit the downside through dynamic portfolio management.This will be done by investing in equity & equity related instruments and active use of debt,money market instruments & derivatives.The equity portfolio will be built on basis "Helio's Elimination Investing" philosophy-based on eight fundamental  screening factors that have repeatedly proven to be effective in weeding out poor performers,gravitating towards winners,and creating a sustainable outperformance profile.

The investment strategy will be to normally maintain gross equity and equity related exposure between 65% -100% and the net equity exposure between 30% to 80%.Various derivative strategies would be used for hedging against market headwinds. Addressing the media Mr. Sameer Arora,the main Founder &Fund Manager  of Helios Capital said," Why the investor should invest in Helios Balanced Advantage Fund: Mr.Samir Arora has an investing experience of 29 years.

   Growth Potential with balanced allocation.
   Attempts to limit downside risk by hedging,tweaking debt.
  Endeavors to allocate =/> 65% into equities,which will provide the scheme with equity fund taxation.
  Units can be redeemed on any Business Day at NAV based price.
  Risk mitigation & rigorous screening.
  Fund Managers with more than 25 years of combined Experience .
Consistency & Disciplined investing.

The Minimum Application amount will be Rs.5000/- & in multiples of Re.1 thereafter.

Please Note: Mutual Fund investments are subject to market risks,read all scheme related documents carefully.
                                                     
                                                 * 









 

Wednesday, February 21, 2024

THE FEDERATION OF INDIAN GRANITE AND STONE INDUSTRY ELECTED NEW PRESIDENT & GENERAL SECRETARY FOR THE TERM 2024-2026.

 The Federation of Indian Granite and Stone Industry (FIGSI) announced the election of Mr.S.Krishna Prasad as President and Mr.Manoj Kumar Singh as the General Secretary for the term 2024-2026.FIGSI is actively involved in the development of the natural stone & Granite industry. FIGSI also organises trhe STONA exhibition every Two Years. The President, Mr.S.Krishna Prasad,is the Managing Director of M/s Prasad Granites with a legacy of spanning over 50 years. Mr.Manoj Kumar Singh is the Director of M/s Metro Granites & Marbles & ManagingPartner of M/s Metro stones with its operations in more than 40 countries.


The next  STONA 2025 & 16th International Granite & Stone Fair  will be held in Bengaluru at Bangalore International Exhibition Centre (BIEC) from 12th TO 15th February,2025.


Mr.S.Krishna Prasad,President expressed his vision as follows"My primary goal shall be to actively engage for increased visibility and branding of  our Federation while upholding the values that define us.Togetherness and interdependence would be the key words in my journey and as President".He also said that there should be a policy for Waste Disposal . He also said that Karnataka's policy is encouraging for the industry. FIGSI also set up
Two Skill Development Centres in Hosur (Tamilnadu) and in Jaipur (Rajasthan).

Sunday, February 18, 2024

RELENTO ANNOUNCES STRATEGIC GLOBAL EXPANSION & LAUNCH OF AI-FIRST LAB & ' RELENTO CARES INITIATIVE'

 RELENTO, a global leader in AI driven business advisory& consulting services,announced a key milestone in their growth story with the launch of AI-First Lab,a global innovation & incubator Hub,at its new state-of-the-art office at IBC Knowledge Park in Bengaluru,Karnataka.The Company also unveiled its Relento Cares inititiative,a community service engagement program focused on uplifting local under privileged & underserved communities across the globe by bridging the digital divide.Through the launch of  Relento cares Initiative,the Company has pledged 1 Million USD towards this global community service initiative.As part of the Relento Cares Initiative, the Company is committed  towards building & equipping a new computer Lab along with additional class rooms at Neraluru Government School with an aim to support Local Bengaluru Community says Mr.Venkatesh Kodangal,Chief Strategy Officer.

" our AI Lab provides a dual purpose platform that supports real world applications and acts as a collaborative hub to nurture innovation.It serves as a beacon for academic institutions across the globe"says Mr.T.P.Vincent,Chief Technology Officer.


Mr.Rajan Gaur,CEO,Relento said, " As part of our global expansion strategy,this new office and AI Innovation Lab in Bengaluru will be a catalyst for our next phase of growth & support our mission to build an AI - first world in collaboration with our customers and partners."

Thursday, February 15, 2024

TATA CONSULTANCY SERVICES (TCS) WORLD 10K BENGALURU ON SUNDAY,28,APRIL,2024. CALLED ENDENDIGU BENGALURU-FOREVER BENGALURU.

Procam International, pioneers of the distance running movement  in India  announced the 16th edition of the World Athletics Gold Label Road Race TCS World 10K Bengaluru scheduled on Sunday,28th April,2024from new venue i.e Field Marshal Sam Manekshaw Parade Ground .The World's Premier 10K with a total Prize money of USD 2,10,000,attracts some of the leading Indian& International athletes along with  amateur runners from across the globe.Registration for all races commence on Thursday,15th February at 07.00 AM & will conclude onFriday,29th March,at 11.59 PM as soon as running places are filled ,whichever is earlier.Register now at : https://tcsworld10k.procam.in.To encourage women's participation,a limited number of spots are set aside for women who donot possess a timing certificate.Registration under these criteria will be based on a first come,first served basis.



Thursday, February 8, 2024

APOLLO CANCER CENTRES (ACC)- FIRST PRIVATE HOSPITAL IN INDIA TO SUCCESSFULLY COMPLETE CarTCELL THERAPY - NOW INTRODUCES " MADE IN INDIA",CAR T CELL PROGRAM.

Apollo Cancer Centre (ACC),successfully complete CAR-T cell program and to further augment it,the hospital group will now provide access "Made In India" CAR-T cell therapy.CAR-T cell therapies,often known as ""Living Drugs' involve the extraction of a patient's T-Cells (a type of white blood cells whose function is to fight cancer cells,through a process known as Aphersis.These T-Cells are then genetically modified by a safe vehicle (Viral Vector) in a controlled laboratory setting,so that they express modified connectors on their surface called Chimeric Antigen Receptors (CAR's).These CAR's are specifically designed to recognise a protein which is abnormally expressed on certain cancer cells.They are then multiplied to a desired dose,and infused directly into the patient.

CAR-T cell therapies have gained global recogntion for their unparalleled success in transforming the lives of patients with challenging B-cell malignancies. Over 25,000 patients have benefitted worldwide from this therapeutic model.

Dr.Aditya Murali,Senior consultant - Medical & Haemato Oncology,ACC,Bangalore ,sharing insights into the success of the program,he said"having successfully treated patients with imported drugs,we are now poised to treat them with indigenously built therapy".

Dr.Neema Bhat,Consultant- Haematology & Paediatric Oncology,ACC,Bangalore said,"This milestone signifies a new chapter in our fight against cancer,offering renewed hope &possibilities to those battling these conditions".

On this occassion,Mr.Dinesh Madhavan,President,Group Oncology & International,Apollo Hospitals Enterprises Limited,said,"The indigenously built CAR-T treatment,NexCAR19 reflects our commitment to provide transformative & cutting edge cancer care.Apollo Cancer Centres is not just changing the narrative,we are rewriting the possibilities of giving better treatment outcome for cancer patients across India & beyond'.


Dr.Manish Mattoo,CEO,Karnataka region,Apollo Hospitals, said," we are proud to be the first in India to achieve the milestone of groundbreaking success in CAR-T cell Therapy & this achievement reflects our dedication to pushing healthcare boundaries & delivering impactful solutions to the community".

In a layman's language,CAR-T cell therapy  reprogramme the body's immunity by harnessing the resources of the  body of the patient to fight by using the body's immunity.This treatment is mainly used for blood cancer Now.

Wednesday, February 7, 2024

ASTER CMI HOSPITAL UNVEILS A PATH BREAKING INNOVATION IN AI - ENDOWMENT TO THE FUTURE OF HEALTH CARE.

 Aster CMI Hospital,charges ahead as a Health care patron with its groundbreaking innovative technology, which supports the health experts on various aspects of treatment such as analyzing vast amounts of data that could lead to accurate diagnosis of diseases earlier,developing new treatment options, and immediate monitoring of vitals for various specialties. 

AI Carpal Tunnel Syndrome (CTS) is one such technology that is developed by the neurology department  which is poised to revolutionize nerve ultra sound diagnostics. This technology redfines,diagnoses and screens efficiently.It can identify the median nerve in ultra sound videos and detect CTS with the highest accuracy (95%)making a significant leap in health care innovation.The AI tool signifies a transformative stride towards precision and efficiency in CTS diagnostics,marking a new era in healthcare.

Mr.Ramesh Kumar.S.CEO,Aster Hospitals said," The hospital has been at the forefront,seamlessly weaving human expertise with AI to usher in a new era in healthcare excellence and actively engaging in collaborative efforts with providers,researchers and innovators to unlock the full potential of AI for the greater good of humanity".

Commenting on the occasion,Dr.Lokesh Bathala,Lead Consultant Neurology, said," This Lab is an exemplification to the unlimited potential of AI in Health Care.These AI tools can prevent long term complications & improve the quality of life.It can also minimize the need for repetetive examinations and invasive procedures,reducing patient's discomfort and anxiety.While the AI tools significantly reduce the inference time,it is important to note that the final diagnosis will always be carried out by the physician". This transformative technology -enabled tool marks new dawn in health care says       Dr.Nitish Shetty, DM Healthcare.




Dr.Phanindra,from  Indian Institute of Science who has set up the Lab at the Hospital said,: It is just the beginning & AI redefines diagnosis & screening"


Tuesday, January 16, 2024

KARNATAKA BANK AND CLIX CAPITAL ENTER INTO CO-LENDING PARTNERSHIP THROUGH YUBI PLATFORM.

Karnataka Bank Ltd.,a leading Private sector Bank and Clix Capital,one of India's fastest growing new age NBFC's have entered into a strategic digital co-lending partnership through Yubi Co.lend platform.This partnership is focused on providing loans to the Indian MSME sector which is one of the biggest contributors to India's GDP and employment growth.The agreement is in line with the Reserve Bank Of India's guidelines and co-lending by banks and NBFC's to priority sectors.  

This partnership combines Karnataka Bank's low cost of funds end to end digital capabilities & expertise to offer credit facilities to this segment along with Clix Capital's strong & easy lending platform and robust due diligence.The partnership aims to provide seamless fencing solutions, conveniently and economically in digital manner,thereby enabling both the partners to draw upon each other's strengths to serve the unserved.The agreement was signed in Bengaluru today.


Speaking on the collaboration,Mr.Srikrishnan H, Managing Director &CEO,Karnataka Bank said,"By this arrangement,the much needed liquidity at affordable rates for the MSME sector will be a reality.Clix Capital & Karnataka Bank will jointly address the MSME's requirements adding impetus to the micro credit facilities to this segment keeping in mind the sustainable economic growth for the country".

Mr.Rakesh Kaul,CEO,Clix Capital Said," Our efforts along with Karnataka Bank will empower the MSME to fulfil their aspirations of seeking seamless &affordable business loans to grow.With this partnership,we will bring to the table our tech prowess,and agility to understand and underwrite segments that largely remain underserved".

Mr.Sekhar Rao,Executive Director,Karnataka Bank,said," the tie up shall leverage technology & digital solutions to seamlessly extend wide range of financial products to MSME sector".

Karnataka Bank is celebrating their centenary year this year.

Saturday, January 13, 2024

APOLLO REVOLUTIONIZES PROSTATE CANCER SCREENING FOR INDIAN MEN WITH GROUNDBREAKING STUDY.

In a monumental stride towards advancing prostate cancer in India,Apollo Hospitals,the world's largest integrated health care provider,has unveiled ground breaking findings in its latest study,'Determining age-specific prostate -specific antigen for healthy Indian men" published in the prestigeous Indian Journal of urology led by DR.N,Raghavan and Dr.Sanjai Addla,from Apollo Chennai and Apollo,Hyderabad respectively.Thee study involved nearly 1,00,000 healthy men across diverse age groups and regions in India establishing new reference values for prostate specific antigen (PSA)specific to the Indian demographic.

        PSA is an established blood marker for early diagnosis and monitoring of treatment  for prostate cancer .Since 1993,International norms for normal PSA values have been based on a study from the USA and the same have been adopted in India.The western standards quiet often were found to be ill suited for the Indian population over to diverse genetic demarcations.This latest groundbreaking Apollo study reveals that PSA values in India differ,prompting the establishment of new tailored standards.Key findings include age specific  PSA standards,a progressive increase in PSA levels with age,and Indian specific PSA values facilitating earlier detection in younger men. 

Dr.Sangita Reddy,Joint Managing Director,Apollo Hospitals, said,"This landmark study ushers a transformative moment in India's prostate cancer care landscape,which resonates with our mission to conquer cancer at every touchpoint possible".

Thursday, January 11, 2024

RAM MANDIR- GRAND INAUGURATION ON 22nd JANUARY,2024 AT AYODHYA.

 In the happiness of Ram Mandir Verdict, we would have forgotten the lawyer 92 year old then,now 96 years old Mr.K.Parasaran  who argued for the Ram Janma Bhoomi case in Supreme Court.  He is a Senior Supreme Court Lawyer  and his legal career spans over Six decades.He served as Attorney General of India between 1983 to 1989.He is considered as PITAMAH of Indian Bar. He was also nominated to Rajya Sabha from 2012 to 2018. His attendance in Rajya Sabha was 81% even at the age of 90.He was awarded Padma Bhushan & Padma Vibhushan.

He argued the Ram Janma Bhoomi  case in Supreme Court   bare foot standing for more than 4 hours at the age of 92 years. That was his faith towards Lord Ram. Even when the Judge requested him to take seat and continue the argument,he said he has argued all cases standing for his clients till date.Now,Lord himself is his client, How can I sit & argue ?,he said.

Monday, December 18, 2023

ASTER CMI HOSPITAL LAUNCHES HEART FAILURE CLINIC AND DAYCARE CENTRE.

 Aster CMI Hospital today launched Heart Failure Clinic and expanded cardiac expertise with a one of its kind Day Care facility for Heart failure management that will provide integrated medical services to heart failure patients.These units will reduce log term hospitalisation and minimise mortality and morbidity to the patients with  heart failure symptoms.Inaugurating the clinic, Mrs. Ashwini  Puneeth Rajkumar, renowned Kannda Film producer,

 
said,Heart related ailments are on the rise in India and there is immediate need for such dedicated clinics that can educate the public on do's and don'ts of healthy living, and the importance of regular screenings and early medical interventions".

"Specialised Clinics like this are proactive answers for heart failure patients and is a ' win-win situation for individuals & society" says Dr.Nagamalesh,U.M.Lead Consultant ,Cardiology, Interventional Cardiologist ,DirectorHeart Failure,Transplant & MCS clinic,Aster CMI Hospital,Bangalore.

Speaking at the launch  Mr.SGS Lakshmanan,COO,Aster CMI Hospital,Bangalore Said," The Heart Failure clinic & Day Care Facility is monitored by multi disciplinary experts and dedicated  Cardiologists. We have successfully conducted 9 Heart transplants in an impressively brief timeframe,thanks to our multi disciplinary team's collaborative approach "